ADARx
Healthcare Access & Wellbeing
Messenger RNA targeting for creating life-saving therapeutics.
Impact Rating
Messenger RNA targeting for creating life-saving therapeutics.
Company Overview
ADARx Pharmaceuticals focuses on editing messenger Ribonucleic Acid (mRNA) transcripts using adenosine deaminase enzymes. Their therapeutics target and correct single-point mutations on mRNA, restoring desired and functional protein production. ADARx’s growing pipeline of ribonucleic acid targeting therapeutics targets various diseases, including genetic, cardiometabolic, complement-mediated, and central nervous system, enabling patients to quickly treat incurable genetic mutations.
ADARx Pharmaceutical's Impact
ADARx is committed to providing effective and safe therapeutics to patients who suffer from intractable diseases.
ADARx Core Mission and Values
ADAR is an acronym for Adenosine Deaminase Acting on RNA and also means ‘wide’ or ‘great’, used to describe the opportunities of their RNA targeting platform.
Current Investors
Investors include Ascenta Capital, Bain Capital Life Sciences, Blackrock, HBM Healthcare Investments.
Leadership & Team
Zhen Li
CEO
Dr. Li has more than two decades of diverse experience in the pharmaceutical and biotech industries, previously serving as Senior VP at Arrowhead Pharmaceutical. Dr. Li received her Ph.D. in Chemistry and Chemical Biology from Harvard University.
Christopher Claeboe
Vice President
Dr. Claeboe has extensive research in CGMP drug substance and product manufacturing through various stages of clinical development to commercialization. Dr. Claeboe previously served as at ChemoCentryx, Inc., in which he contributed significantly to the development of their recently approved drug Taveneos.
Melissa Fisher
Vice President
Dr. Fisher has over 15 years of oligonucleotide industry experience, previously serving as Execute Director at Ionis Pharmaceuticals. Dr. Fisher is a registered patent attorney with the USPTO and received her Ph.D. in Biochemistry and Molecular Biology from the University of California.
Rui Zhu
Vice President
Dr. Zhu is an experienced drug hunter with a proven track record in the oligonucleotide field, previously the Program Lead at Arrowhead Pharmaceuticals where he conducted 5 Phase I clinical trials. Dr. Zhu recieved his Ph.D. in Organic Chemistry from Tsinghua University.
How does ADARx plan to use funds raised?
The Series C financing will fund ADARx's clinical programs, including drug candidates for multiple complement-mediated diseases and hereditary angioedema, and support the development of innovative mRNA silencing or editing candidates.
Risks associated with ADARx
ADARX Pharmaceuticals may face challenges manufacturing ADAR1 at scale as RNA editing therapeutics are a new type of therapy. ADARx is working to overcome these challenges with the assistance of CMO's to help with this tricky manufacturing process.
How are ADARx leveraging technology?
ADARx Pharmaceuticals have developed proprietary RNA delivery platforms and technology for silencing or editing target mRNA. Its proprietary RNA targeting platform, includes oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies.
Research by: Bilal Ismail
Latest News in Life Sciences
08/25/25, 05:59 PM
What's Going On With Novo Nordisk Stock Monday? - Novo Nordisk ( NYSE:NVO )
At least 20 deviations linked to hair contamination have been reported since July 2024. Investigations often lacked root cause analysis and CAPA effectiveness checks. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here → The U.S.
Source: Benzinga
Read more →
08/25/25, 05:38 PM
Nutex Health ( NUTX ) Securities Suit Alleges Fraud and Financial Misstatements - Hagens Berman
SAN FRANCISCO, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- A new class-action lawsuit alleges that Nutex, a hospital and healthcare services company, engaged in a fraudulent scheme with a third-party billing firm to inflate its revenues, leading to millions of dollars in losses for investors.
Source: Benzinga
Read more →08/25/25, 05:23 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NEW YORK, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ( "Ultragenyx" or the "Company" ) RARE. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Source: Benzinga
Read more →